Abstract
Filipino thyroid cancer patients have higher incidences of high-risk pathological features and greater age-adjusted mortality rates (AAMR) and mortality risk. These findings warrant further investigation into better understanding the connection between the greater incidence of high-risk characteristics and increased mortality in Filipinos.
Introduction
While thyroid cancer incidence has been rising globally, Filipino Americans are disproportionately affected. The specific reasons for this disparity remain poorly understood, partly because existing research often aggregates all Asian Americans into a single "Asian/Pacific Islander" (API) category. This masking of ethnic subgroups prevents a granular understanding of how thyroid cancer behaves specifically within the Filipino community. This study aims to determine whether the higher mortality seen in Filipinos is due to late-stage presentation, more aggressive tumor biology, or underlying health disparities.
Methodology
This retrospective, records-based study utilized data from the California Cancer Registry (CCR), analyzing 97,948 cases diagnosed between 1988 and 2018. California provides a robust dataset as it is home to nearly 1.6 million Filipinos.
Key methodological steps included:
- Subgroup Disaggregation: Breaking down the API category into specific ethnicities (Filipino, Chinese, Japanese, Korean, Vietnamese, South Asian, and Other Southeast Asian).
- Statistical Modeling: Binary logistic regression was used to calculate the odds of presenting with high-risk characteristics (e.g., Stage IV or T4 tumors).
- Survival Analysis: Kaplan-Meier estimates for overall survival and multivariate Cox proportional hazards regression for mortality risk, adjusting for age, sex, stage, socioeconomic status (SES), and comorbidities.
- Mortality Metrics: Calculation of age-adjusted mortality rates (AAMR) and Average Annual Percent Change (AAPC).
Results
Aggressive Pathological Features
Filipinos present with significantly more aggressive disease compared to other groups. They exhibited a higher likelihood of Stage IV disease (13.31% of cases), T4 tumor stage (OR 1.46), and N1 nodal stage compared to Non-Hispanic Whites, Blacks, and Hispanics. Specifically, Filipinos were 1.52 times more likely to have Stage IV disease than Non-Hispanic Whites.
Survival and Mortality
Filipinos had the highest AAMR at 1.22 deaths per 100,000 in 2015. The 10-year overall survival for Filipinos was 83.6%, notably lower than Hispanics (87.1%) and other API groups (87.0%). Even after adjusting for SES and comorbidities, the mortality risk for Filipinos remained significantly higher (HR 1.10), suggesting that the disparity is not solely due to access to care or wealth.
The "API" Mask
The study underscores the danger of aggregate data. Filipinos had worse 5-year and 10-year overall survival than the combination of all other API subgroups. Aggregating these groups hides the specific risks faced by the Filipino community.
Discussion
The findings indicate that Filipinos are dealing with more resistant or advanced disease at the outset. Interestingly, they were more likely to receive total thyroidectomies and radiation, yet still faced higher mortality.
Limitations and Future Work
Race and ethnicity data in registries are often self-reported, potentially leading to misclassification. Furthermore, the CCR lacks granular data on genetic mutations (e.g., BRAF V600E, RET alterations) that drive aggressive cancer. Potential historical radiation exposure among Filipino healthcare workers who immigrated in the 1970s/80s is another factor that could not be directly tested.
The persistent mortality gap and higher incidence of high-risk characteristics in Filipinos warrant urgent investigation into biological and environmental drivers. Future research should focus on molecular profiling to develop targeted screening and treatment strategies for this community.
Summary updated